Home › Compare › PEARW vs EPRT

PEARW vs EPRT: Dividend Comparison 2026

PEARW yields 33898.31% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PEARW wins by $9.963396520724352e+21M in total portfolio value
10 years
PEARW
PEARW
● Live price
33898.31%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9.963396520724352e+21M
Annual income
$9,905,911,559,981,649,000,000,000,000.00
Full PEARW calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — PEARW vs EPRT

📍 PEARW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPEARWEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PEARW + EPRT cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PEARW pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PEARW
Annual income on $10K today (after 15% tax)
$2,881,355.93/yr
After 10yr DRIP, annual income (after tax)
$8,420,024,825,984,401,000,000,000,000.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, PEARW beats the other by $8,420,024,825,984,401,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PEARW + EPRT for your $10,000?

PEARW: 50%EPRT: 50%
100% EPRT50/50100% PEARW
Portfolio after 10yr
$4.981698260362176e+21M
Annual income
$4,952,955,779,990,824,000,000,000,000.00/yr
Blended yield
99.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

PEARW
No analyst data
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PEARW buys
0
EPRT buys
0
No recent congressional trades found for PEARW or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPEARWEPRT
Forward yield33898.31% ✓3.92%
Annual dividend / share$2.00 ✓$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29% ✓
Portfolio after 10y$9.963396520724352e+21M$63.4K ✓
Annual income after 10y$9,905,911,559,981,649,000,000,000,000.00 ✓$12,840.73
Total dividends collected$9.959616773768018e+21M$37.9K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: PEARW vs EPRT ($10,000, DRIP)

YearPEARW PortfolioPEARW Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$3,400,531$3,389,830.51$11,205$505.18+$3.39M → PEARW
2$1,080,949,041$1,077,310,473.14$12,672$682.46+$1080.94M → PEARW
3$321,205,007,173$320,048,391,699.27$14,490$930.48+$321204.99M → PEARW
4$89,224,694,578,678$88,881,005,221,002.70$16,786$1,282.69+$89224694.56M → PEARW
5$23,169,738,996,241,900$23,074,268,573,042,710.00$19,753$1,791.56+$23169738996.22M → PEARW
6$5,624,691,175,493,529,000$5,599,899,554,767,550,000.00$23,677$2,541.64+$5624691175493.50M → PEARW
7$1,276,516,462,323,700,300,000$1,270,498,042,765,922,300,000.00$29,008$3,672.99+$1276516462323700.25M → PEARW
8$270,840,549,707,403,520,000,000$269,474,677,092,717,130,000,000.00$36,463$5,425.08+$270840549707403520.00M → PEARW
9$53,724,262,376,359,350,000,000,000$53,434,462,988,172,430,000,000,000.00$47,238$8,221.57+$53724262376359346176.00M → PEARW
10$9,963,396,520,724,353,000,000,000,000$9,905,911,559,981,649,000,000,000,000.00$63,385$12,840.73+$9.963396520724352e+21M → PEARW

PEARW vs EPRT: Complete Analysis 2026

PEARW — Stock

Pear Therapeutics, Inc. engages in developing and commercializing software-based medicines. The company has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurologic conditions. Its products include PearConnect, a patient service center for prescription digital therapeutics; reSET for the treatment of substance use disorder; reSET-O for the treatment of opioid use disorder; and Somryst for the treatment of chronic insomnia. The company was founded in 2013 and is based in Boston, Massachusetts.

Full PEARW Calculator →

EPRT — REIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this PEARW vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PEARW vs SCHDPEARW vs JEPIPEARW vs OPEARW vs KOPEARW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.